A meta-analysis of clinical benefit rates for fulvestrant 500 mg versus alternative therapies for treatment of postmenopausal, estrogen receptor-positive advanced breast cancer

被引：1
|
作者：
Robertson, J. F. R.
Zefei, J.
Di Leo, A.
Ohno, S.
Pritchard, K. I.
Ellis, M.
Bradbury, I.
Campbell, C.
机构：
[1] Univ Nottingham, Div Breast Surg, Nottingham NG7 2RD, England
[2] Chinese Peoples Liberat Army, Hosp 307, Beijing, Peoples R China
[3] Hosp Prato, Sandro Pitigliani Med Oncol Unit, Prato, Italy
[4] Canc Inst Hosp, Breast Oncol Ctr, Tokyo, Japan
[5] Sunnybrook Odette Canc Ctr, Toronto, ON, Canada
[6] Univ Toronto, Toronto, ON, Canada
[7] Baylor Coll Med, Houston, TX 77030 USA
[8] Frontier Sci, Kingussie, Inverness, Scotland
来源：
CANCER RESEARCH | 2016年 / 76卷
关键词：
D O I：
10.1158/1538-7445.SABCS15-P5-14-01
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P5-14-01
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Impact of progesterone receptor status on rates of recurrence in estrogen receptor-positive breast cancer patients: A systematic review and meta-analysis
    Boland, Michael
    Ryan, Eanna
    Dunne, Emma
    Bhatt, Nikita
    Lowery, Aoife
    ANNALS OF SURGICAL ONCOLOGY, 2019, 26 : 227 - 227
  • [32] Benefit of paclitaxel in estrogen receptor-negative versus estrogen receptor-positive early breast cancer - Reply
    Henderson, IC
    Norton, L
    Berry, DA
    JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (23) : 4465 - 4466
  • [33] Independent central review of clinical benefit rates in FIRST: a Phase II comparison of fulvestrant 500 mg with anastrozole 1 mg as first-line endocrine therapy for postmenopausal women with hormone receptor positive advanced breast cancer
    Lindemann, J. P. O.
    Robertson, J. F. R.
    Ellis, M. J.
    Menu, Y.
    Macpherson, E. J.
    Ghiorghiu, D. D. C.
    EJC SUPPLEMENTS, 2009, 7 (02): : 282 - 282
  • [34] COST EFFECTIVENESS OF FULVESTRANT 500 MG IN ENDOCRINE THERAPY-NAIVE WOMEN WITH HORMONE RECEPTOR-POSITIVE ADVANCED BREAST CANCER IN THE UK
    Livings, C.
    Jones, N.
    Bertranou, E.
    Large, S.
    Phelps, H.
    Ekman, M.
    Telford, C.
    VALUE IN HEALTH, 2017, 20 (09) : A435 - A435
  • [35] Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial
    Robertson, John F. R.
    Bondarenko, Igor M.
    Trishkina, Ekaterina
    Dvorkin, Mikhail
    Panasci, Lawrence
    Manikhas, Alexey
    Shparyk, Yaroslav
    Cardona-Huerta, Servando
    Cheung, Kwok-Leung
    Philco-Salas, Manuel Jesus
    Ruiz-Borrego, Manuel
    Shao, Zhimin
    Noguchi, Shinzaburo
    Rowbottom, Jacqui
    Stuart, Mary
    Grinsted, Lynda M.
    Fazal, Mehdi
    Ellis, Matthew J.
    LANCET, 2016, 388 (10063): : 2997 - 3005
  • [36] Efficacy and safety of fulvestrant in postmenopausal patients with hormone receptor-positive advanced breast cancer: a systematic literature review and meta-analysis (vol 171, pg 535, 2018)
    Wang, Jiayu
    Xu, Binghe
    Wang, Wenna
    Zhai, Xiaoyu
    Chen, Xuelian
    BREAST CANCER RESEARCH AND TREATMENT, 2019, 173 (02) : 487 - 487
  • [37] FALCON: A phase III randomised trial of fulvestrant 500 mg vs. anastrozole for hormone receptor-positive advanced breast cancer
    Ellis, M. J.
    Bondarenko, I.
    Trishkina, E.
    Dvorkin, M.
    Panasci, L.
    Manikhas, A.
    Shparyk, Y.
    Cardona-Huerta, S.
    Cheung, K-L.
    Philco-Salas, M. J.
    Ruiz-Borrego, M.
    Shao, Z.
    Noguchi, S.
    Grinsted, L. M.
    Fazal, M.
    Stuart, M.
    Robertson, J. F.
    ANNALS OF ONCOLOGY, 2016, 27
  • [38] Real-world data of fulvestrant as first-line treatment of postmenopausal women with estrogen receptor-positive metastatic breast cancer
    Blancas, I.
    Olier, C.
    Conde, V.
    Bayo, J. L.
    Herrero, C.
    Zarcos-Pedrinaci, I.
    Carabantes, F.
    Baena-Canada, J. M.
    Cruz, J.
    Ruiz-Borrego, M.
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [39] Fulvestrant 250mg versus Anastrozole 1 mg in the Treatment of Advanced Breast Cancer: a Meta-Analysis of Randomized Controlled Trials
    Gong, Dan-Dan
    Man, Chang-Feng
    Xu, Juan
    Fan, Yu
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2014, 15 (05) : 2095 - 2100
  • [40] Real-world data of fulvestrant as first-line treatment of postmenopausal women with estrogen receptor-positive metastatic breast cancer
    I. Blancas
    C. Olier
    V. Conde
    J. L. Bayo
    C. Herrero
    I. Zarcos-Pedrinaci
    F. Carabantes
    J. M. Baena-Cañada
    J. Cruz
    M. Ruiz-Borrego
    Scientific Reports, 11
12345